Beijing Scitop Bio Tech Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 25.93%

Beijing Scitop Bio Tech Co Ltd (300858) has an Asset Resilience Ratio of 25.93% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Beijing Scitop Bio Tech Co Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥525.73 Million
≈ $76.93 Million USD Cash + Short-term Investments

Total Assets

CN¥2.03 Billion
≈ $296.66 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2025)

This chart shows how Beijing Scitop Bio Tech Co Ltd's Asset Resilience Ratio has changed over time. See 300858 equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Beijing Scitop Bio Tech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Beijing Scitop Bio Tech Co Ltd worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥525.73 Million 25.93%
Total Liquid Assets CN¥525.73 Million 25.93%

Asset Resilience Insights

  • Very High Liquidity: Beijing Scitop Bio Tech Co Ltd maintains exceptional liquid asset reserves at 25.93% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Beijing Scitop Bio Tech Co Ltd Industry Peers by Asset Resilience Ratio

Compare Beijing Scitop Bio Tech Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 84.34%
3SBio Inc
F:83B
Biotechnology 10.64%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
Biotechnology 0.02%
Novavax Inc
NASDAQ:NVAX
Biotechnology 53.87%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Beijing Scitop Bio Tech Co Ltd (2020–2025)

The table below shows the annual Asset Resilience Ratio data for Beijing Scitop Bio Tech Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 5.46% CN¥110.21 Million
≈ $16.13 Million
CN¥2.02 Billion
≈ $295.43 Million
-10.03pp
2024-12-31 15.49% CN¥296.73 Million
≈ $43.42 Million
CN¥1.92 Billion
≈ $280.31 Million
-19.61pp
2023-12-31 35.10% CN¥635.26 Million
≈ $92.96 Million
CN¥1.81 Billion
≈ $264.87 Million
+19.39pp
2022-12-31 15.70% CN¥281.17 Million
≈ $41.14 Million
CN¥1.79 Billion
≈ $262.01 Million
+6.91pp
2021-12-31 8.80% CN¥91.55 Million
≈ $13.40 Million
CN¥1.04 Billion
≈ $152.29 Million
-8.06pp
2020-12-31 16.85% CN¥168.40 Million
≈ $24.64 Million
CN¥999.25 Million
≈ $146.22 Million
--
pp = percentage points

About Beijing Scitop Bio Tech Co Ltd

SHE:300858 China Biotechnology
Market Cap
$601.50 Million
CN¥4.11 Billion CNY
Market Cap Rank
#11453 Global
#3277 in China
Share Price
CN¥15.60
Change (1 day)
+3.59%
52-Week Range
CN¥14.51 - CN¥25.45
All Time High
CN¥35.93
About

Beijing Scitop Bio-tech Co., Ltd. researches, develops, produces, and sells probiotic, postbiotics, and microecologival preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women's health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy … Read more